Skip to content

ENGN

enGene Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · CA

$1.91
+0.00%
Ask drillr

Year over year

Reported trailing growth

Revenue
-100.0%
EBITDA
-45.3%
EBIT
+95.4%
EPS
+85.3%
Free cash flow
-9.3%
Operating cash flow
-10.1%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
+36.1%
EPS

Three-year CAGR

Revenue
EBITDA
EBIT
-97.7%
Net income
EPS
-56.8%
Free cash flow

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026